View Post

Clone of Endocrine Therapy Before Surgery Results in Different Outcomes in Black vs. White Women With Breast Cancer

In In The News by Barbara Jacoby

From: cityofhope.org A study led by City of Hope, one of the largest cancer research and treatment organizations in the United States, found that Black women with Stage 1 or 2 breast cancer were almost three times more likely than white women to have tumor shrinkage from hormone therapy delivered prior to surgery, yet Black women were more likely than …

View Post

Challenges in Treating ETR

In In The News by Barbara Jacoby

From:.physiciansweekly.com For a study, researchers sought to identify the molecular processes causing Endocrine therapy resistance (ETR) using a thorough genomic investigation of breast tumors. Pre-treatment and post-treatment tumor samples from 35 estrogen receptor-positive breast cancer patients who had neoadjuvant and adjuvant endocrine therapy revealed that 3 developed intrinsic resistance, 19 acquired resistance, and 13 remained susceptible. Neoadjuvant changes in tumor …

View Post

Intrinsic Tumor Subtyping Is Key To Breast Cancer Treatment

In In The News by Barbara Jacoby

By: Jason Harris From: onclive.com Perou is the May Goldman Shaw Distinguished Professor of Molecular Oncology, codirector of the Computational Medicine Program, faculty director of the UNC Lineberger Bioinformatics Group, codirector of the UNC Lineberger Breast Cancer Research Program, and a professor in the department of genetics at the University of North Carolina Lineburger Comprehensive Cancer Center. He is also …

View Post

Some US Women Not Getting ET for Curable Breast Cancer

In In The News by Barbara Jacoby

By: Sharon Worcester From: medscape.com Many patients with early breast cancer are being undertreated, concludes a novel study that examined the management of such patients across various geographical regions across the United States. A standard treatment for early breast cancer is endocrine therapy (ET), with drugs such as tamoxifen and aromatase inhibitors. But the study found that it was not …

View Post

Bone fractures are common after breast cancer endocrine therapy

In In The News by Barbara Jacoby

By: Amerigo Allegretto From: auntminnie.com Wrist and vertebral fractures are most prevalent in women who have received endocrine therapy for invasive breast cancer, according to research published November 17 in JAMA Network Open. A team led by Dr. Joan Lo from Kaiser Permanente Northern California highlighted fracture characteristics in their study of over 5,000 women. The study also included clinically diagnosed …

View Post

Lynne Wagner, PhD, on Cancer-Related Cognitive Impairment in Early Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Jeff Minerd From: medpagetoday.com TAILORx trial provided new insights into chemoendocrine therapy versus endocrine therapy alone Cancer-related cognitive impairment is common during adjuvant chemotherapy and may persist for months or years after treatment. The TAILORx trial provided an opportunity to prospectively assess patient-reported cognitive impairment among women with early breast cancer who were randomly assigned to chemoendocrine therapy or …

View Post

Survival Consistent for Women With Early-Stage Breast Cancer Despite Surgery Delays

In In The News by Barbara Jacoby

By: Maggie L. Shaw From: ajmc.com Delays in surgery to treat early-stage breast cancer and receiving neoadjuvant endocrine therapy did not decrease survival odds among female patients, authors report in the Journal of the American College of Surgeons. Overall delays in surgical procedures to treat early-stage breast cancer, particularly estrogen-sensitive early-stage disease, as well as receiving neoadjuvant endocrine therapy (NET) …

View Post

Factors of Therapy Delivery Tied to Adherence in Nonmetastatic Breast Cancer

In In The News by Barbara Jacoby

By: Conference Insider From: oncnet.com The method by which adjuvant endocrine therapy is delivered to patients with breast cancer is associated with rate of adherence, according to data being presented by Joan Marie Neuner, MD, MPH, Medical College of Wisconsin, Milwaukee, and colleagues at the virtual 2020 ASCO Annual Meeting. “Over 50% of breast cancer patients prescribed adjuvant endocrine therapy…are …

View Post

Adjuvant Chemoendocrine Therapy May Be Associated With Cognitive Impairment

In In The News by Barbara Jacoby

By: Hannah Slater From: cancernetwork.com Results from a subgroup of the TAILORx trial, published in the Journal of Clinical Oncology, suggested that adjuvant chemoendocrine therapy is associated with significantly greater cancer-related cognitive impairment (CRCI) compared with endocrine therapy alone among women with breast cancer at 3 and 6 months.1 However, these differences receded over time, with no significant differences observed at …

View Post

Certain Factors Linked with Discontinuing Breast Cancer Therapy

In In The News by Barbara Jacoby

From: webwire.com For women with hormone receptor–positive breast cancer, long-term endocrine therapy can greatly reduce the risk of recurrence. Many women, especially those in underserved populations, do not continue treatment, however. A new Psycho-Oncology study uncovers some of the factors that may be involved. In the study of 1,231 women who completed questionnaires, 59% reported at least one barrier to adhering to …